AI-generated analysis. Always verify with the original filing.
Enlivex Therapeutics Ltd. reported that the Rain Foundation launched an OpenClaw and AI agent interface enabling anyone to create live prediction markets via a single prompt without coding or gatekeepers, and announced a $5 million grant program for developers. As a major RAIN token holder, Enlivex views this as enhancing Rain's position and potential revenue growth via 2.5% trading volume buy-and-burn.